4//SEC Filing
GELLERT MICHAEL E 4
Accession 0000899243-17-026031
CIK 0001492422other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 4:25 PM ET
Size
11.4 KB
Accession
0000899243-17-026031
Insider Transaction Report
Form 4
GELLERT MICHAEL E
10% Owner
Transactions
- Conversion
Common Stock
2017-11-13+798,068→ 943,989 total - Conversion
Series B Preferred Stock
2017-11-13−545,454→ 0 total→ Common Stock (255,721 underlying) - Conversion
Series C Preferred Stock
2017-11-13−556,830→ 0 total→ Common Stock (261,054 underlying) - Conversion
Series A Preferred Stock
2017-11-13−600,000→ 0 total→ Common Stock (281,293 underlying)
Footnotes (1)
- [F1]The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001018650
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 4:25 PM ET
- Size
- 11.4 KB